RxDoctor Payments Data

Hilary Akpudo, MD

Psychiatry · Kingwood, TXNPI 1437461530

Payments from drug & device makers

$1,383in general payments, 2019–2025

Across 70 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$367
  • Teva Pharmaceuticals USA, Inc.$182
  • Sanofi$158
  • AbbVie$133
  • Neuronetics, Inc.$106
  • Alkermes, Inc.$99
  • plus $337 from 6 others

What the payments were for

  • Food & beverage$1,383100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,383 in reported general payments places this provider in the 70th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$128,527
Medicare patients
141
Services billed
1,392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$41,277
SuboxoneBuprenorphine Hcl/Naloxone Hcl12$8,747
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl14$4,340
Paliperidone ErPaliperidone34$3,301
Clozapine27$2,245
Oxcarbazepine65$1,244
Hydroxyzine Hcl75$1,126
Aripiprazole48$960
Benztropine Mesylate130$882
Haloperidol34$837
Divalproex Sodium89$732
Hydroxyzine Pamoate78$700
Temazepam65$624
Gabapentin75$558
Olanzapine28$441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$367$41,27713 claims
Indivior Inc.Suboxone$66$8,74712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Kingwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →